Cantor Fitzgerald Predicts REGN FY2025 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Regeneron Pharmaceuticals in a research note issued on Tuesday, April 22nd. Cantor Fitzgerald analyst C. Gould expects that the biopharmaceutical company will post earnings of $26.38 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $695.00 target price on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share.

REGN has been the topic of a number of other research reports. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Bank of America cut their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a report on Thursday, April 17th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a “buy” rating for the company in a report on Wednesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $949.60.

Read Our Latest Report on REGN

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $599.76 on Thursday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a 50-day simple moving average of $638.93 and a 200-day simple moving average of $728.60. Regeneron Pharmaceuticals has a 52 week low of $525.99 and a 52 week high of $1,211.20. The stock has a market capitalization of $65.57 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm earned $11.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Pamalican Asset Management Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $4,915,000. Intact Investment Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $356,000. Rhenman & Partners Asset Management AB boosted its stake in shares of Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock valued at $30,956,000 after buying an additional 4,457 shares in the last quarter. Principal Financial Group Inc. raised its position in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after acquiring an additional 2,828 shares in the last quarter. Finally, Fagan Associates Inc. lifted its holdings in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after acquiring an additional 3,832 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.59%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.